Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth
Addiction · 2025
DOI: 10.1111/add.70251 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addiction, 2025. Verfasst von Silvi C Goldstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of Rhode Island, Kingston, RI, USA. Hauptthemen laut MEDLINE: Naltrexone, Alcoholism, Harm Reduction, Narcotic Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and Aims In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm‐reduction treatment improved alcohol outcomes and physical health‐related quality of life (PH‐QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.
Design
Secondary study of a four‐arm RCT.
Setting
Community settings serving people experiencing homelessness in the US Pacific Northwest.
Participants
Adults aged 21–65 (N = 308) with alcohol use disorder (AUD) who experienced past‐year homelessness.
Intervention
In the parent RCT, participants were randomized to brief behavioral harm‐reduction treatment for AUD + extended‐release naltrexone (HaRT‐A + XR‐NTX); HaRT‐A + placebo; HaRT‐A alone, or services‐as‐usual control. Measurement We tested whether baseline outcomes, trial inclusion, data missingness, treatment adherence, side effects, and treatment effects on alcohol frequency, quantity, alcohol‐related harm, urinary ethyl glucuronide, and PH‐QoL differed by race, ethnicity, and sex assigned at birth.
Findings
Race, ethnicity and sex assigned at birth were not associated with differential trial inclusion, missingness, treatment adherence or side effects with one exception: the Multiracial/other people of color (POC) group attended fewer HaRT‐A sessions than the white group (odds ratio [ OR ] = 0.49, p = 0.03, 95% confidence interval [CI] [0.25, 0.95]). There were no statistically significant moderators of the behavioral HaRT‐A effect; however, Multiracial/other POC race ( B = ‐3.34, p = 0.03, 95% CI [−6.35, −0.34]) and sex assigned at birth ( B = 2.43, p = 0.04, 95% CI [0.14, 4.73]) moderated the XR‐NTX versus placebo effect on one variable: PH‐QoL. Simple slope analysis indicated the Multiracial/other POC group who received placebo showed improvement on PH‐QoL ( dy/dx = 2.61, p = 0.003, 95% CI [0.91, 4.31]); the XR‐NTX group did not ( dy/dx = −0.22, p = 0.79, 95% CI [−1.90, 1.45]). Among XR‐NTX recipients, the female group ( dy/dx = 2.89, p < 0.001, 95% CI [1.53, 4.25]) showed faster improvement rates than the male group ( dy/dx = 1.19, p = 0.02, 95% CI [0.23, 2.16]) on PH‐QoL.
Conclusion
Race, ethnicity and sex assigned at birth were largely not associated with trial inclusion, data missingness, treatment adherence, side effects, or outcomes in a combined harm‐reduction treatment and extended‐release naltrexone randomised clinical trial for alcohol use disorder (AUD). Although Multiracial/other people of color (POC) participants attended fewer brief behavioral harm‐reduction treatment for AUD sessions, they did not differ from white participants on alcohol and physical health‐related quality of life outcomes. Among participants receiving extended‐release naltrexone (XR‐NTX), women showed greater improvement than men on physical health‐related quality of life. Compared with white participants, Multiracial/other POC participants who received XR‐NTX showed less improvement than those who received placebo. Given their post hoc nature and limited power, findings are hypothesis‐generating. They suggest the equitable utility of behavioral harm‐reduction treatment and the importance of assessing sociodemographic differences in AUD treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychology, University of Rhode Island, Kingston, RI, USA.
- Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Providence, RI, USA.
- School of Medicine, University of Washington, Seattle, WA, USA.
ORCID-Profile: Silvi C Goldstein, Nicole H Weiss, Sarah W Feldstein Ewing, Susan E Collins
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Goldstein, S. C., Weiss, N. H., Yang, M., Feldstein Ewing, S. W., & Collins, S. E. (2025). Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth. Addiction. https://doi.org/10.1111/add.70251
Vancouver
Goldstein SC, Weiss NH, Yang M, Feldstein Ewing SW, Collins SE. Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth. Addiction. 2025. doi:10.1111/add.70251
BibTeX
@article{Goldstein2025,
author = {Goldstein, Silvi C and Weiss, Nicole H and Yang, Manshu and Feldstein Ewing, Sarah W and Collins, Susan E},
title = {Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth},
journal = {Addiction},
year = {2025},
doi = {10.1111/add.70251}
}
EUVIMED